Jagsonpal Pharmaceuticals per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹6.83₹6.40₹8.26₹8.49₹10.20
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹6.71₹6.31₹8.22₹8.46₹10.20
₹41.24₹41.24₹36.14₹70.88₹60.65
₹44.91₹42.89₹40.47₹78.94₹90.36
—₹6.99₹8.33₹13.30₹15.33
₹6.99₹6.99₹8.28₹13.21₹15.20
6.76.76.62.62.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,547 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS10.208.498.266.406.83
Diluted EPS10.208.468.226.316.71
Book Value per Share60.6570.8836.1441.2441.24
Revenue per Share90.3678.9440.4742.8944.91
Cash Flow per Share15.3313.308.336.99—
Free Cash Flow per Share15.2013.218.286.996.99
Shares Outstanding (cr)2.62.66.66.76.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.